FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:715-717 August 16, 2007 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hughes, M. D. Related Article by Stein, J. H. Related Article by The DAD Study Group PubMed Citation

To the Editor: We agree with the Perspective article by Hughes and Williams (April 26 issue)¹ that a more detailed presentation of data from the well-conducted Data Collection on Adverse Effects of Anti-HIV Drugs (DAD) Study Group collaboration² may help to disentangle several variables that potentially affect the risk of myocardial infarction among persons infected with human immunodeficiency virus type 1 (HIV-1). First, data on the nadir CD4+ lymphocyte count, but not the recent CD4+ count, were presented in relation to the risk of myocardial infarction. Inflammation may trigger an acute myocardial infarction by activating prothrombotic mechanisms, and the patient's . . . [Full Text of this Article]

This article has been cited by other articles:

• Schambelan, M., Wilson, P. W.F., Yarasheski, K. E., Cade, W. T., Davila-Roman, V. G., D'Agostino, R. B. Sr, Helmy, T. A., Law, M., Mondy, K. E., Nachman, S., Peterson, L. R., Worm, S. W., for Working Group 5, (2008). Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. Circulation 118: e48-e53 [Full Text]